Iα,25-dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells

Prostate

Volumn 68, Issue 7, 2008, Pages 773-783

  Serda, Rita E ^a   Bisoffi, Marco ^b   Thompson, Todd A ^c   Ji, Ming ^b   Omdahl, John L ^b   Sillerud, Laurel O ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Androgen receptor; Prostate; PSMA; Vitamin D

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CALCITRIOL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SMALL INTERFERING RNA; VITAMIN D RECEPTOR; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; NITRILE; PROSTATE SPECIFIC ANTIGEN; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL SURFACE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RNA TRANSLATION; CELL PROLIFERATION; DOSE RESPONSE; DRUG SCREENING; GENE SILENCING; GENETICS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE SILENCING; HUMANS; MALE; MEMBRANE PROTEINS; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TOSYL COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 43049130408     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20739     Document Type: Article

References (35)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22(4):232-240.
2. Brawer MK, Crawford ED, Labrie F, Mendoza-Valdes A, Miller PD, Petrylak DP. Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol 2001;S59-S68.
3. Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl 2004;25(3):305-313.
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
5. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9(17):6357-6362.
6. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48(2): 326-334.
7. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5(10):2674-2681.
8. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57(17):3629-3634.
9. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10(5A):1307-1311.
10. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70(12):2861-2869.
11. Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. Vitamin D: A modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 1990;37(6):873-876.
12. Bikle DD. 1,25(OH)2D3-regulated human keratinocyte proliferation and differentiation: Basic studies and their clinical application. J Nutr 1995;125: (6 Suppl):1709S-1714S.
13. Darwish HM, DeLuca HF. Identification of a 1,25-dihydroxyvitamin D3-response element in the 5′-flanking region of the rat calbindin D-9k gene. Proc Natl Acad Sci USA 1992;89(2):603-607.
14. Haussler MR, Jurutka PW, Hsieh JC, Thompson PD, Selznick SH, Haussler CA, Whitfield GK. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Bone 1995;17(2 Suppl):33S-38S.
15. Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138(8):3290-3298.
16. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004;23(19):3350-3360.
17. Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS, Russell PJ, Heston WD, Molloy PL. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FO LH1. Genomics 2001;73(3):243-254.
18. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 2002;285(1-2):247- 256.
19. Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005;435(1):1-14.
20. Ghosh A, Wang X, Klein E, Heston WD. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005;65(3):727-731.
21. O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000;45(2):149-157.
22. Adler AJ, Danielsen M, Robins DM. Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci USA 1992;89(24):11660-11663.
23. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54(7):1807-1811.
24. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280(8):6511-6519.
25. Herdick M, Carlberg C. Agonist-triggered modulation of the activated and silent state of the vitamin D(3) receptor by interaction with co-repressors and co-activators. J Mol Biol 2000;304(5):793-801.
26. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J. Purification and functional characterization of the human N-CoR complex: The roles of HDAC3, TBL1 and TB LR1. EMBO J 2003;22(6):1336-1346.
27. Dunlop TW, Vaisanen S, Frank C, Carlberg C. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets. J Steroid Biochem Mol Biol 2004;89-90(1-5):257-260.
28. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003;278(7):5052-5061.
29. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-540.
30. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 2000;60(9):2317-2322.
31. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59(11):2511-2515.
32. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140(3):1205-1212.
33. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277(29):26321-26326.
34. Murayama A, Kim MS, Yanagisawa J, Takeyama K, Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J 2004;23(7):1598-1608.
35. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993;46:759-765.